Coherent Market Insights joins Pharmaconex 2026 as strategic partner

Coherent Market Insights will bring market intelligence and advisory support to Pharmaconex 2026, the pharmaceutical exhibition set for Sept. 1-3 in Cairo. The partnership is designed to help manufacturers, suppliers, investors and other attendees navigate supply chain shifts, regulation and investment opportunities across MENA.

Why it matters: - The partnership gives Pharmaconex 2026 attendees access to market intelligence at a time when pharmaceutical manufacturing is being reshaped by supply chain diversification, regulatory change and new investment activity. - CMI’s report and outreach are meant to help exhibitors, visitors and other stakeholders make more informed business decisions during and after the event.

What happened: - Coherent Market Insights joined Pharmaconex 2026 as a Strategic Partner. - Pharmaconex 2026 is organized by Informa Egypt LLC and runs Sept. 1-3, 2026, at the Egypt International Exhibition Centre in Cairo. - The event is positioned as one of the leading pharmaceutical industry platforms in the MENA region. - The partnership connects CMI with pharmaceutical manufacturers, API producers and suppliers, CDMOs, healthcare innovators, distributors and investors across the value chain.

The details: - CMI’s core contribution is an Executive Market Intelligence Report titled Global Pharmaceutical Manufacturing & API Market – Trends, Investment Outlook & Forecast 2026–2033. - The report covers global manufacturing capacity, API growth trajectories, supply chain localization strategies, regulatory developments, the competitive landscape and likely investment flows. - CMI will use its B2B network and digital platform to extend the partnership announcement and report findings beyond Cairo. - CMI is also providing integrated PR and press release distribution to B2B professionals in 32 countries. - The outreach plan has two phases: pre-event communication about the partnership, then post-event coverage of major discussions, insights and outcomes. - More information about Pharmaconex 2026 is available at the event website.

Between the lines: - The partnership reflects a broader push in the pharmaceutical industry to replace fragmented market chatter with research-backed intelligence. - CMI is using the exhibition as both a live event and a distribution channel for longer-term market insight. - The model suggests trade shows are increasingly being used to drive content, audience reach and post-event engagement, not just in-person networking. - Raj Shah, founder and CEO of CMI, said the industry is entering a transformative phase driven by manufacturing strategy shifts, supply chain changes, innovation and emerging market opportunities.

What's next: - CMI will promote the partnership ahead of the event and follow it with coverage of the key takeaways from Pharmaconex 2026. - Attendees are expected to use the report and event discussions to assess opportunities in manufacturing, APIs and related investment themes over the coming years. - Pharmaconex 2026 will continue to serve as a regional meeting point for the pharmaceutical value chain across MENA and internationally.

The bottom line: - CMI is turning Pharmaconex 2026 into a vehicle for market intelligence, not just an exhibition, with the aim of helping industry players make sharper decisions in a fast-changing sector.